.png)
CardiacSense
CE/FDA-cleared medical watch — continuous A-Fib/arrhythmia detection (PPG/ECG) + multi-vital monitoring for RPM/telemedicine
Latest event found: 12 Oct 2026 · 8 days ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
CardiacSense is moving from Israeli medical-wearable development toward international commercialization, with a Dubai distribution agreement, planned Tel Aviv listing, and continued cuffless blood-pressure and cardiac-monitoring development. Public evidence indicates meaningful regulatory and engineering progress, but also financing and execution risk during the scale-up phase.
Efficiency Ratio
A relatively small team appears to be producing substantial regulatory, product, and international-market output, although the limited public evidence of realized revenue and customer conversion constrains confidence in operating efficiency.
Evidence Signals
CardiacSense signed a distribution agreement with a Dubai-based company to market and sell its medical watch across the United Arab Emirates, valued at up to eight million dollars over four years.
CardiacSense was reported as preparing to go public on the Tel Aviv Stock Exchange.
The company listed CS System 6 as scheduled for release in the fourth quarter of 2026.
- About
- Israeli medical-device company (CardiacSense Ltd.; HQ Caesarea, Israel — North Industrial Park; founded 2009; ~11-50 staff) that makes a CE- and FDA-cleared 'medical watch' for long-term continuous vital-sign monitoring and real-time arrhythmia detection on the wrist. Using proprietary PPG and/or ECG sensors, it continuously detects atrial fibrillation and other arrhythmias (company-reported 99.2% sensitivity/specificity), and also tracks respiration rate (to monitor CHF/COPD patients), SpO2, heart-rate variability, skin temperature, sleep-apnea and activity, with a physician portal; a cuff-less absolute blood-pressure capability has been in development. Positioned for Remote Patient Monitoring (RPM), Chronic Care Management (CCM) and telemedicine. Defense relevance: continuous casualty/remote-vitals monitoring fits the C12-03 monitoring cluster (peer to Biobeat, Neteera, Oxitone and Cnoga), but CardiacSense is civilian-first with no defense credential.
- Tags
- #wearable #arrhythmia #atrialfibrillation #cufflessbp #vitalsigns #ecg #ppg #monitoring #fda #dualuse